Serologicals closes Toronto facility

By Lisa Kerner

Erie, Pa., Jan. 6 - Serologicals Corp. will close its facility in Toronto and move all manufacturing of its cell culture products to Kankakee, Ill. These actions are expected to be complete by the first half of the year.

During the past six months, Serologicals has expanded the production capacity at its Kankakee facility by more than 50%. It can now can meet both current and anticipated demand for Serologicals' EX-CYTE cell culture product.

The closing and move are in response to the company's ongoing plant consolidation and rationalization initiative. Serologicals plans to focus on reducing ongoing operating costs while improving the efficiency of its facilities and supply chain management activities.

The Toronto facility, as well as an unused Lawrence, Kan. facility, will be written down to net realizable value for inclusion in the company's 2005 fourth quarter financials. Both facilities will be prepared for sale.

"While these are very difficult decisions, we feel these actions are necessary to enable the company to be more competitive in our marketplace, will enable us to better serve our customers and will enhance the long term profitability of the corporation," said David A. Dodd, Serologicals' president and chief executive officer, in a news release.

Serologicals, headquartered in Atlanta, develops consumable biological products in support of biological research, drug discovery, and the bioprocessing of life-enhancing products.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.